Evotec SE (LON:0IRF)
London · Delayed Price · Currency is GBP · Price in EUR 5.39
+0.23 (4.50%)
At close: Dec 23, 2025
Evotec SE Revenue
In the year 2024, Evotec SE had annual revenue of 796.97M EUR with 1.99% growth. Evotec SE had revenue of 163.89M in the quarter ending September 30, 2025, a decrease of -5.75%.
Revenue
796.97M EUR
Revenue Growth
+22.68%
P/S Ratio
1.26
Revenue / Employee
168.14K EUR
Employees
4,740
Market Cap
834.47M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 332.72M | 779.52% |
| Dec 31, 2009 | 42.68M | 3.07M | 7.75% |
| Dec 31, 2008 | 39.61M | 6.73M | 20.46% |
| Dec 31, 2007 | 32.89M | -7.69M | -18.95% |
| Dec 31, 2006 | 40.58M | -1.26M | -3.02% |
| Dec 31, 2005 | 41.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| AstraZeneca | 43.24B |
| HSBC Holdings | 43.13B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| Barclays | 26.02B |
Evotec SE News
- 15 days ago - Evotec: How Low A Company May Go While Still Being Attractive - Seeking Alpha
- 15 days ago - Sandoz Completes Acquisition Of Just-Evotec Biologics - Nasdaq
- 15 days ago - Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz - Accesswire
- 19 days ago - Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome - Accesswire
- 5 weeks ago - Evotec (EVO) Secures $5M Milestone from Bristol Myers Squibb - GuruFocus
- 5 weeks ago - Evotec gets $5M milestone payment from Bristol Myers after FDA accepts new drug application - Seeking Alpha
- 5 weeks ago - Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - Accesswire
- 6 weeks ago - Evotec SE 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha